The Cracking Cancer Podcast

Navigating the Complexity of Clinical Trials with Max Doppelt. Episode 42.

The Cracking Cancer Podcast

Show Notes

In this high-stakes episode of "Cracking Cancer," Dr. Kyle Concannon and Samantha Murrell are joined by Max Doppelt, an engineer-turned-caregiver who transformed his mother’s terminal diagnosis into a mission for systemic change. Max shares the harrowing reality of navigating the "ivory tower" of oncology, where regulatory burdens and institutional silos often prevent patients from accessing the very drugs that could save them. From the heartbreak of failing trial screenings due to rigid exclusion criteria to the bold, life-saving decision to source a next-generation TKI from China during a trade war, this conversation pulls back the curtain on the logistical "nightmare" of the current trial system. The trio discusses why the burden of research often falls on the terminally ill and how Max is using his "special nerd powers" to bridge the gap. He introduces Patient Data Vault, a privacy-first AI platform designed to automate the clinical trial search, turning a list of thousands of irrelevant options into a curated handful of actionable leads. It’s an episode about patient empowerment, the "action layer" of AI, and the lengths a family will go to when the standard of care is no longer enough.

Key Takeaways:

The Regulatory Gap The Problem with "Ivory Towers" Inclusion/Exclusion Paradox AI as the Great Equalizer Proactive "Second Opinion" Strategy

Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast) Giving.CU.EDU/CrackingCancer

Chapters: (00:00) Understanding Clinical Trials (01:56) Max's Experience with Clinical Trials (05:40) Samantha's Clinical Trial Journey (08:37) Challenges in Finding the Right Trial (12:41) Max's Search for a Clinical Trial (25:16) The China Solution (31:07) Navigating Treatment Options: A Personal Journey (41:02) The Burden on Patients to Find Trials (48:50) Innovative Solutions: Patient Data Vault (58:48) The Future of AI in Healthcare

The Cracking Cancer Podcast's main focus is to further education about cancer and its effects on people and communities through continued discussion and to raise funds for the continued research of cancer treatments and positive outcomes. All raised proceeds go directly to the continued upkeep of this podcast and cancer research. To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org

Attributions The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License

X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos

More from The Cracking Cancer Podcast

Oct 22, 2026

In this episode of Cracking Cancer, host Dr. Kyle Concannon reunites with patient advocate Samantha Murrell and science communicator Dr. Rob Swanda to tackle some of the most persistent, widespread myths and misconceptions in oncology. The team explores the emotional and practical realities of navigating a cancer diagnosis, addressing online health claims, and clearing up common misunderstandings about treatments, genetics, and screening. Dr. Kyle and Samantha break down why pathology and diagnostic scans are not always straightforward, how "Stage IV" and "terminal" are often conflated, and why modern palliative chemotherapy looks vastly different from treatments 30 years ago. They also address dangerous online misinformation—such as the claim that biopsies or mammograms spread cancer, or that alternative therapies alone can cure metastatic disease. Finally, the panel emphasizes the critical role of open communication with your care team, particularly regarding potential interactions between targeted therapies and over-the-counter supplements.

Oct 15, 2026

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by breast surgical oncologist Dr. Monique Gary (Dr. Mo) and Stage IV metastatic breast cancer advocate Lindsay Campbell. The panel unpacks the complex and often overwhelming world of breast cancer surgery, moving step-by-step from the initial consultation through the operating room experience to post-operative recovery. Lindsay shares her personal surgical path—navigating the emotional frustration of an 11-week scheduling delay due to tumor growth and operating room availability, which forced a pivot from a planned double mastectomy with DIEP flap reconstruction to an immediate lumpectomy. Dr. Mo demystifies surgical decision-making, explaining how tumor grade, genetic mutations (such as BRCA1/2), and hormone/HER2 status shape surgical choices. The panel also covers practical OR preparations—such as nerve blocks, pre-medication for nausea, surgical drain management, and handling "time toxicity"—offering actionable insights for patients preparing for their own surgical journeys.

Oct 8, 2026

In this episode of Cracking Cancer, host Dr. Kyle Concannon is joined by breast radiologist Dr. Deepa Sheth and Stage IV metastatic breast cancer advocate Lindsay Campbell. Lindsay shares her personal story of being diagnosed at age 38 after facing nearly a year of medical delays. Despite noticing visible skin dimpling and localized pain, she was repeatedly turned away because she was under the traditional screening age of 40 and lacked a felt mass due to deep chest-wall tumor placement. It was only after her father was diagnosed with breast cancer and identified as BRCA-positive that she was able to secure a diagnostic workup. Dr. Sheth and Lindsay break down the mechanics of screening versus diagnostic imaging, explaining how 2D/3D mammography, targeted ultrasound, and breast MRI function together. Dr. Sheth highlights the critical importance of free risk-assessment tools—such as the Tyrer-Cuzick model—which can identify high-risk individuals (>20% lifetime risk) who qualify for screening starting as early as age 30. The panel also tackles the federal mandate surrounding dense breast tissue, insurance coverage nuances, and why patients must trust their intuition when advocating for timely care.

Oct 1, 2026

In this episode of Cracking Cancer, host Dr. Kyle Concannon sits down in person with science communicator Rob Swanda, PhD, to tackle one of the most persistent and anxiety-inducing topics in oncology: Does sugar feed cancer? Rob and Kyle break down the biochemistry behind how the body processes carbohydrates, deconstruct online misconceptions, and address the real-world harm caused when cancer patients starve themselves of vital nutrition out of fear. Rob explains the Warburg Effect—a phenomenon where cancer cells preferentially use glucose via fast, anaerobic glycolysis to generate rapid cellular energy—and clarifies why cell culture findings in a Petri dish do not translate to human metabolism. Dr. Kyle discusses human glucose homeostasis, highlighting how the liver and muscles maintain steady blood sugar through gluconeogenesis and glycogen breakdown regardless of dietary intake. The hosts issue a stark warning against extreme restrictions that lead to cancer cachexia (muscle and weight wasting) and explain why, for patients without uncontrolled diabetes, enjoying food and maintaining caloric intake is far more vital than cutting out sugars.

Sep 17, 2026

In this episode of Cracking Cancer, science communicator Rob Swanda, PhD, is joined by glioblastoma researcher Dr. Julio Sanchez, a postdoctoral fellow at UCLA. Julio pulls back the curtain on early-stage cancer research, shedding light on the quiet, rigorous, and often high-failure world of preclinical science that takes place long before a new drug ever reaches a clinical trial. Julio details the transition from in vitro cell line work to complex in vivo mouse models, explaining why glioblastoma remains one of the most notoriously aggressive and difficult-to-treat brain cancers. He highlights his lab's recent publication in Cancer Research, which introduced next-generation, CRISPR-engineered mouse models that far better mirror human glioblastoma pathology and the tumor immune microenvironment compared to traditional cell lines developed in the 1970s. The pair also explore the rise of therapeutic mRNA vaccines and organoid platforms, and discuss why the scientific method is fundamentally a mindset built on resilience, critical thinking, and iterative problem-solving.

See all episodes →